Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levonorgestrel
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
Levonorgestrel IUS (LNG-IUS) is a long-acting reversible contraceptive (LARC) system that releases the synthetic progestin levonorgestrel directly into the uterine cavity. Developed by Bayer (originally Schering AG), the system consists of a T-shaped polyethylene frame with a steroid-reservoir that provides continuous, low-dose release of the hormone. Its primary mechanism of action involves thickening cervical mucus to prevent sperm penetration, thinning the endometrial lining, and inhibiting sperm motility and function. The LNG-IUS is highly effective for contraception and is also indicated for the treatment of heavy menstrual bleeding (menorrhagia). Various versions exist with different release rates and durations of use, including Mirena (20 µg/day), Kyleena (17.5 µg/day), and Skyla/Jaydess (14 µg/day).
- Brand names
- MirenaSkylaKyleenaJaydessLilettaLevosert
- Other names
- levonorgestrel-releasing intrauterine systemlevonorgestrel intrauterine systemLNG-releasing IUSlevonorgestrel-releasing intrauterine deviceLNG-IUD
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on levonorgestrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levonorgestrel.